XML 55 R41.htm IDEA: XBRL DOCUMENT v3.10.0.1
NOTES PAYABLE (Tables)
6 Months Ended
Jan. 26, 2019
Debt Disclosure [Abstract]  
Schedule of Debt [Table Text Block]
The Company’s long-term debt consisted of the following:
(in thousands)
Average Interest Rate at
January 26, 2019
 
Maturity Year
 
January 26,
2019
 
July 28,
2018
Term Loan Facility
6.65%
 
2019-2025
 
$
1,903,000

 
$

ABL Credit Facility
3.81%
 
2023
 
1,242,004

 

Other secured loans
5.74%
 
2023
 
40,396

 

Former ABL Credit Facility
 
 
 
 

 
210,000

Former Term Loan Facility
 
 
 
 

 
110,000

Debt issuance costs, net
 
 
 
 
(60,631
)
 
(1,164
)
Original issue discount on debt
 
 
 
 
(43,638
)
 

Long-term debt, including current portion
 
 
 
 
$
3,081,131

 
$
318,836

Less: current portion of long-term debt obligations
 
 
 
 
(115,795
)
 
(10,000
)
Long-term debt
 
 
 
 
$
2,965,336

 
$
308,836

Schedule of Line of Credit Facility
The assets included in the Condensed Consolidated Balance Sheets securing the outstanding borrowings under the ABL Credit Facility on a first-priority basis, and the unused available credit and fees under the ABL Credit Facility, were as follows:
Assets securing the ABL Credit Facility (in thousands)(1):
January 26, 2019
Certain inventory assets included in Inventories and Current assets of discontinued operations
$
2,297,742

Certain receivables included in Receivables and Current assets of discontinued operations
$
953,726

(1)
The ABL Credit Facility is also secured by all of the Company’s pharmacy scripts, which are included in Long-term assets of discontinued operations in the Condensed Consolidated Balance Sheets as of January 26, 2019.
Unused available credit and fees under the ABL Credit Facility (in thousands, except percentages):
January 26, 2019
Outstanding letters of credit
$
76,763

Letter of credit fees
1.375
%
Unused available credit
$
731,234

Unused facility fees
0.375
%